About Synphora AB

About company

While working at Pharmacia in the late 80’s Johan Stjernschantz was the co-inventor of latanoprost, a prostaglandin F2α receptor agonist, and the therapeutic principle behind Xalatan® which radically improved the treatment of glaucoma. He was also in charge of the entire development of Xalatan®, including the regulatory approval in Europe and the USA.